Drug intelligence / Profile preview

Rejuvxl

Development stage: Phase 2
Lead developer: AION Healthspan
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Rejuvxl (AION-301) is an immunomodulatory cell therapy being developed by AION Healthspan. It utilizes mesenchymal stromal cells (MSCs) that are designed to deliver protective molecules to modulate inflammation and promote tissue repair. The therapy is being investigated for several inflammatory and autoimmune conditions, including Graft Versus Host Disease (GVHD), Chronic Kidney Disease (CKD), Type 1 and Type 2 Diabetes, and acute lung indications. It is currently in Phase 1/2 clinical development for GVHD, with other indications in the IND-enabling stage.

Brand names: Rejuvxl

Beyond the preview

Go deeper on Rejuvxl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rejuvxl.

Explore the full profile